CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 70 enrolled
Drug / intervention
Selumetinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01206140
NCT01206140Phase 2Completed
CompareCT.gov

Randomized, Phase II Trial of AZD6244 Alone and AZD6244 Plus Temsirolimus for Soft-Tissue Sarcomas

National Cancer Institute (NCI)·interventional·Posted Sep 21, 2010·Updated Oct 5, 2015

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Selumetinib, and 1 other intervention for Recurrent Adult Soft Tissue Sarcoma and 2 related conditions. Completed, enrolled 70 participants across 8 sites.

Detailed Summary

This randomized phase II trial is studying how well giving selumetinib together with or without temsirolimus works in treating patients with metastatic, recurrent, or locally advanced soft tissue sarcoma that cannot be removed by surgery. Selumetinib and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving selumetinib together with temsirolimus is more effective than giving selumetinib alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
CountriesUnited States
CollaboratorsNational Comprehensive Cancer Network

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 21, 2010
Enrollment StartOct 1, 2010
Primary CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 15.8 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Selumetinibdrug

Given PO

Temsirolimusdrug

Given IV